The use of warfarin as part of antithrombotic strategy after transcutaneous aortic valve replacement is not associated with better medium-term outcomes

27 August 2022 (13:15 - 14:00)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Assistant Professor Jwan Naser

Mayo Clinic, Rochester (United States of America)

7 More presentations in this session

Presentation thumbnail

Direct oral anticoagulants compared to vitamin K antagonists for the treatment of left ventricular thrombi

Doctor H. Morgan (London, GB)

Abstract Slides

Presentation thumbnail

Frailty and outcomes in octogenarians with atrial fibrillation treated with edoxaban: ESCAPE study

Doctor G. Denas (Motta Di Livenza, IT)

Abstract Slides

Presentation thumbnail

Oral anticoagulant therapy and decline of kidney function in elderly patients with non-valve atrial fibrillation: real world evidence data

Doctor G. Severini (Catanzaro, IT)

Abstract Slides

Presentation thumbnail

Previous antithrombotic therapy does not have an impact on the in-hospital mortality of patients with upper gastrointestinal bleeding

Doctor M. Hozman (Prague, CZ)

Abstract Slides

Presentation thumbnail

The association of angiotensin-converting enzyme inhibitors and angiotensin 2 receptor blockers with renal protection in patients with SARS-CoV-2

Mr S. Tan (New York, US)

Abstract Slides

Access the full session

Session thumbnail

Challenges in cardiovascular pharmacotherapy in patients who are older or with comorbidities

The Event

Event poster

ESC Congress 2022

27 August 2022 13:15 CET

You may be interested in

Webinar

Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients

Congress Presentation

Antithrombotic therapy in diabetes

Congress Presentation

Contemporary thrombosis management -- state of the state

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources